Table 3.
Drug resistance phenotype (s) b (no. of isolates) |
CAZ | CAZ + AVI | CAZ-AVI MIC50 reduction (fold) | ATM | ATM + AVI | ATM-AVI MIC50 reduction (fold) |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MIC50 | MIC90 | range | MIC50 | MIC90 | range | MIC50 | MIC90 | range | MIC50 | MIC90 | range | |||
Total(76) | 8 | 64 | 0.03–64 | 2 | 64 | 0.016–64 | 4 | 64 | 64 | 1–1024 | 2 | 8 | 0.06–64 | 32 |
MH-NSc or LVX-NS or SXT-NS (60) |
16 | 64 | 0.03–64 | 4 | 16 | 0.016–64 | 4 | 64 | 64 | 1–1024 | 2 | 8 | 0.06–64 | 32 |
MH-Sd and LEV-S and SXT-S (16) |
4 | 8 | 1–16 | 2 | 2 | 0.25–8 | 2 | 64 | 64 | 64 | 2 | 2 | 0.5–64 | 32 |
MDR (2) | NAe | NA | > = 64 | NA | NA | 16- > 64 | NA | NA | NA | 64 | NA | NA | 2–8 | NA |
aMICs are expressed in μg/mL
bCAZ ceftazidime, ATM aztreonam, AVI avibactam, MDR multidrug resistant. Multidrug-resistant isolates were defined as isolates demonstrating resistance to at least one antimicrobial agent from three or more different classes
cNS not susceptible, dS susceptible, eNA not applicable. MIC50s and MIC90s are not presented for groups of fewer than 6 isolates